- Home
- FORR vs ENGN Comparison
FORR vs ENGN Comparison
Compare FORR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- ENGN
- Stock Information
- Founded
- FORR 1983
- ENGN 1999
- Country
- FORR United States
- ENGN Canada
- Employees
- FORR N/A
- ENGN N/A
- Industry
- FORR Diversified Commercial Services
- ENGN
- Sector
- FORR Consumer Discretionary
- ENGN
- Exchange
- FORR Nasdaq
- ENGN Nasdaq
- Market Cap
- FORR 193.5M
- ENGN 191.1M
- IPO Year
- FORR 1996
- ENGN N/A
- Fundamental
- Price
- FORR $9.75
- ENGN $3.51
- Analyst Decision
- FORR
- ENGN Buy
- Analyst Count
- FORR 0
- ENGN 7
- Target Price
- FORR N/A
- ENGN $23.29
- AVG Volume (30 Days)
- FORR 68.4K
- ENGN 76.2K
- Earning Date
- FORR 07-29-2025
- ENGN 09-09-2025
- Dividend Yield
- FORR N/A
- ENGN N/A
- EPS Growth
- FORR N/A
- ENGN N/A
- EPS
- FORR N/A
- ENGN N/A
- Revenue
- FORR $422,269,000.00
- ENGN N/A
- Revenue This Year
- FORR N/A
- ENGN N/A
- Revenue Next Year
- FORR $2.04
- ENGN N/A
- P/E Ratio
- FORR N/A
- ENGN N/A
- Revenue Growth
- FORR N/A
- ENGN N/A
- 52 Week Low
- FORR $8.50
- ENGN $2.65
- 52 Week High
- FORR $20.62
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- FORR 45.09
- ENGN 48.11
- Support Level
- FORR $9.77
- ENGN $3.25
- Resistance Level
- FORR $11.00
- ENGN $3.98
- Average True Range (ATR)
- FORR 0.39
- ENGN 0.26
- MACD
- FORR -0.01
- ENGN -0.00
- Stochastic Oscillator
- FORR 28.21
- ENGN 54.37
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.